Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;8(7):516.
doi: 10.21037/atm.2020.01.26.

No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI

Marco Valgimigli  1 , Felice Gragnano  1
Affiliations
Editorial

No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI

Marco Valgimigli et al. Ann Transl Med. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.01.26). Dr. Valgimigli reports grants and personal fees from Abbott, personal fees from Bayer, personal fees from Daiichi Sankyo, personal fees from Amgen, grants and personal fees from Terumo, personal fees from Alvimedica, grants from Medicure, grants and personal fees from Astrazeneca, personal fees from Idorsia, personal fees from Coreflow, personal fees from Vifor, personal fees from Bristol Myers Squib SA, personal fees from iVascular, outside the submitted work. Dr. Gragnano reports a research grant from the European Society of Cardiology (ESC).

Figures

Figure 1
Figure 1
Benefit or harm of double versus triple antithrombotic therapy in patients with AF having ACS or PCI, based on the individual risk of myocardial infarction or major bleeding. In red, the net benefit of double versus triple therapy is in favor of bleeding; in blue, a net ischaemic harm prevails. Colours intensity refers to greater (dark) or lower (light) extent of benefit or harm. Orange indicates a neutral effect. DAT, double antithrombotic therapy; TAT, triple antithrombotic therapy.
See this image and copyright information in PMC

Comment on

  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Lopes RD, et al. N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17. N Engl J Med. 2019. PMID: 30883055 Clinical Trial.

References

    1. Capodanno D, Huber K, Mehran R, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. J Am Coll Cardiol 2019;74:83-99. 10.1016/j.jacc.2019.05.016 - DOI - PubMed
    1. Lip GYH, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: Past, present and future. Thromb Haemost 2017;117:1230-9. 10.1160/TH16-11-0876 - DOI - PubMed
    1. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J 2018;39:213-60. 10.1093/eurheartj/ehx419 - DOI - PubMed
    1. Calabrò P, Gragnano F, Di Maio M, et al. Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology 2018;69:795-802. 10.1177/0003319718760917 - DOI - PubMed
    1. Leon MB, Baim DS, Popma JJ, et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting. N Engl J Med 1998;339:1665-71. 10.1056/NEJM199812033392303 - DOI - PubMed